Endo v. Fresenius Kabi: Epinephrine Injection Patent Case Ends in 64 Days
Endo Operations Limited sued Fresenius Kabi USA over a generic epinephrine injection product, asserting three U.S. patents covering its Adrenalin® 1 mg/mL injectable solution. The case was filed in Delaware on September 24, 2024, and voluntarily dismissed without prejudice just 64 days later — before the defendant had filed any answer or dispositive motion.
A pre-answer voluntary exit in a multi-patent epinephrine ANDA dispute
On September 24, 2024, Endo Operations Limited filed suit against FK Fresenius Kabi USA, LLC in the U.S. District Court for the District of Delaware, alleging infringement of three U.S. patents — US10130592B2, US9119876B1, and US9295657B1 — each directed to epinephrine injectable formulations. The asserted patents protect Endo’s branded Adrenalin® epinephrine injection product (30 mg base/30 mL; 1 mg/mL), a critical-care vasopressor. Fresenius Kabi’s accused product is a generic multi-dose vial presentation of Epinephrine Injection, USP, 1 mg/mL.
The case closed on November 27, 2024 — just 64 days after filing — when Endo invoked Federal Rule of Civil Procedure 41(a)(1)(A) to voluntarily dismiss the action without prejudice. This procedural mechanism is available as of right when, as here, the defendant has not yet served an answer or a motion for summary judgment. The without-prejudice designation means the dismissal carries no merits adjudication and does not bar Endo from refiling the same claims in the future.
A 64-day lifecycle before any substantive engagement is notably brief and consistent with strategic early exits in Hatch-Waxman litigation — potentially reflecting settlement discussions, a licensing arrangement, or a reassessment of claim scope following FDA or PTAB developments. The public record does not disclose any terms or rationale beyond the procedural basis. Because no merits were decided, the validity and enforceability of the three asserted patents remain fully open questions.
Filing to Voluntary dismissal in 64 days
64 days — resolved before defendant filed any responsive pleading
Voluntarily dismissed: what the Rule 41 exit means for both parties
Rule 41(a)(1)(A): a dismissal as of right
Under Federal Rule of Civil Procedure 41(a)(1)(A), a plaintiff may dismiss an action without a court order — and without prejudice — at any time before the defendant serves an answer or a motion for summary judgment. Fresenius Kabi had not yet done either, making Endo’s voluntary dismissal procedurally straightforward. No judicial approval was required, and no merits finding was made.
No court order requiredWithout prejudice — but what does that mean here?
A dismissal without prejudice does not extinguish the underlying claims. Endo retains the right to refile the same infringement allegations on the same three patents against Fresenius Kabi. A with-prejudice dismissal would have barred refiling. The public record is silent on any agreed terms or conditions attached to this exit, so it is not possible to determine from the docket alone whether the parties reached a private arrangement.
Refiling remains possibleEndo preserves all patent rights and future enforcement options
By dismissing without prejudice before any answer was filed, Endo avoids any risk of an adverse ruling on patent validity or infringement at this stage. All three asserted patents remain intact and enforceable. Endo can monitor Fresenius Kabi’s commercial launch activity and refile if warranted, or pursue alternative routes such as negotiated licensing or a new suit upon expiry of any agreed standstill period.
All three patents intactFresenius Kabi escapes this suit but faces residual patent uncertainty
Fresenius Kabi avoided litigation costs and the risk of a preliminary injunction by never filing a responsive pleading, but the without-prejudice dismissal means the patent overhang persists. Any commercial launch of its 1 mg/mL epinephrine multi-dose vial product would likely require a freedom-to-operate analysis against the three Endo patents, which remain valid and unadjudicated. The risk of a refiled action cannot be excluded.
Patent overhang persistsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Endo Operations Limited | Individual | Pharmaceutical IP licensor — holder of US10130592B2, US9119876B1, and US9295657B1Search in Eureka ↗ |
| Defendant | FK Fresenius Kabi USA, LLC | Company | U.S. subsidiary of Fresenius Kabi AG; generic injectable pharmaceutical manufacturerSearch in Eureka ↗ |
| Plaintiff counsel | Aziz Burgy | Attorney | Counsel for Endo Operations LimitedSearch in Eureka ↗ |
| Plaintiff counsel | Kelly E. Farnan | Attorney | Counsel for Endo Operations LimitedSearch in Eureka ↗ |
| Plaintiff counsel | Ricardo Camposanto | Attorney | Counsel for Endo Operations LimitedSearch in Eureka ↗ |
| Plaintiff counsel | Steven J. Fineman | Attorney | Counsel for Endo Operations LimitedSearch in Eureka ↗ |
| Plaintiff law firm | Richards Layton & Finger PA | Law Firm | Representing Endo Operations LimitedSearch in Eureka ↗ |
| Defendant counsel | John C. Phillips , Jr. | Attorney | Counsel for FK Fresenius Kabi USA, LLCSearch in Eureka ↗ |
| Defendant counsel | Megan C. Haney | Attorney | Counsel for FK Fresenius Kabi USA, LLCSearch in Eureka ↗ |
| Defendant law firm | Phillips, McLaughlin & Hall PA | Law Firm | Representing FK Fresenius Kabi USA, LLCSearch in Eureka ↗ |
| Presiding judge | Judge Maryellen Noreika | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal notice invokes Rule 41(a)(1)(A) explicitly and confirms that Fresenius Kabi had not served an answer or dispositive motion at the time of filing. This framing is significant: it is a procedural dismissal, not a merits ruling. The without-prejudice designation means neither patent validity nor infringement was adjudicated. The phrasing is consistent with a plaintiff exercising a unilateral right of exit rather than responding to any adverse court action, leaving all three asserted patents fully available for future enforcement proceedings.
US10130592B2 — Epinephrine injectable solution formulations
The three asserted patents — US10130592B2, US9119876B1, and US9295657B1 — each originate from U.S. patent applications filed between 2015 and 2016 and are directed to formulations and/or methods of preparation for epinephrine injectable solutions, including the 1 mg/mL concentration used in Endo’s Adrenalin® product. Epinephrine injection is a critical-care active pharmaceutical ingredient used in anaphylaxis, cardiac arrest, and surgical haemostasis, making IP exclusivity commercially significant. These patents cover aspects of formulation stability, pH control, and excipient selection that differentiate branded from generic presentations.
For the injectable pharmaceutical sector, this patent cluster represents a meaningful defensive perimeter around a relatively mature but high-value molecule. Fresenius Kabi, as one of the largest global manufacturers of generic injectables, is a natural ANDA filer for this product category. The three patents’ co-pending status and overlapping claim architecture suggest a layered prosecution strategy designed to extend protection across formulation variables. Competitors targeting the 1 mg/mL epinephrine multi-dose vial market should treat this cluster as a live enforcement risk regardless of the current dismissal’s without-prejudice status.
Should you run an FTO against US10130592B2 and the Adrenalin® patent cluster?
Any pharmaceutical company, contract development and manufacturing organisation (CDMO), or ANDA applicant developing a 1 mg/mL epinephrine injectable solution — particularly in multi-dose vial format — should conduct a freedom-to-operate analysis against US10130592B2, US9119876B1, and US9295657B1 before progressing to commercial launch. The without-prejudice dismissal in this case provides no legal safe harbour; Endo retains full enforcement rights and the patents have never been adjudicated on validity or infringement.
PatSnap Eureka’s FTO Search Agent can map the claim scope of each of the three Endo patents against your proposed formulation parameters — including excipient selection, pH range, and stabiliser concentration — and identify design-around opportunities or potential invalidity arguments based on prior art. Eureka’s prosecution history analysis further surfaces any file wrapper estoppel or claim amendments that may narrow enforceability, giving your development team actionable guidance before regulatory submission.
Run a freedom-to-operate analysis on US10130592B2 to assess your product’s exposure
Run FTO in Eureka →Similar epinephrine injectable patent cases in U.S. federal courts
Cases involving Hatch-Waxman infringement actions over epinephrine and vasopressor injectable formulations in U.S. District Courts, including Delaware.
What this case signals for the injectable pharmaceutical IP landscape
Early voluntary dismissals in Hatch-Waxman suits often reflect off-docket deal-making. Three unadjudicated patents remain in play.
Pre-answer dismissals in ANDA litigation often signal private resolution
In Hatch-Waxman disputes, a voluntary Rule 41(a)(1)(A) dismissal before any responsive pleading is commonly associated with confidential settlement, consent judgment, or licensing arrangements reached outside the court record. The 64-day window here is consistent with that pattern, though no terms are publicly confirmed.
Three unadjudicated epinephrine patents remain enforceable against the market
US10130592B2, US9119876B1, and US9295657B1 were never tested on validity or infringement grounds. Any company developing or commercialising a 1 mg/mL epinephrine injectable — particularly multi-dose vial formats — should conduct FTO analysis against these patents before launch. The patents’ application priority dates span 2015–2016.
Limited v FK — key questions answered
Endo Operations Limited filed a patent infringement action against FK Fresenius Kabi USA, LLC in the Delaware District Court on September 24, 2024, asserting three U.S. patents over epinephrine injectable formulations. The case was voluntarily dismissed without prejudice on November 27, 2024 — 64 days after filing — before Fresenius Kabi had filed any answer or dispositive motion.
Endo asserted three U.S. patents: US10130592B2, US9119876B1, and US9295657B1. All three are directed to epinephrine injectable solution formulations and relate to Endo’s branded Adrenalin® product (epinephrine injection, 1 mg/mL). The patents originate from U.S. applications filed between 2015 and 2016.
A voluntary dismissal without prejudice under Rule 41(a)(1)(A) means Endo chose to end the lawsuit without any court ruling on the merits. No finding was made on patent validity or infringement. Critically, ‘without prejudice’ means Endo retains the right to refile the same claims against Fresenius Kabi in the future. The public record does not disclose the reason for the dismissal or any settlement terms.
No. Because the case was dismissed without prejudice before any substantive proceedings, no court made any ruling on the validity or enforceability of US10130592B2, US9119876B1, or US9295657B1. All three patents remain in force and are available for future enforcement actions by Endo against Fresenius Kabi or any other party.
The dismissal does not create a legal safe harbour for Fresenius Kabi. The three Endo patents remain valid and unadjudicated, and Endo could refile an infringement action — for example, upon FDA ANDA approval or commercial launch. Fresenius Kabi would typically need to rely on its ANDA Paragraph IV certifications or a negotiated resolution to commercialise its multi-dose vial epinephrine product without litigation risk.
PatSnap Eureka searches patents and litigation data to answer instantly.